Micafungina Accordpharma

Micafungin, the active ingredient in Micafungina Accordpharma, is an echinocandin presented as an intravenous solution for intravenous use. It treats invasive candidiasis, Candida esophagitis and is used for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungina Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Micafungina is an echinocandin antifungal indicated for several serious Candida infections.

Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections in adult and pediatric patients. Candida esophagitis: eradication of esophageal Candida infection causing dysphagia and pain. Prophylaxis in hematopoietic stem cell transplantation: prevention of Candida infection during the high‑risk transplant period.

Micafungina may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever or chills during infusion. - Elevated liver enzymes (ALT, AST). - Nausea or vomiting. - Headache. - Rash or pruritus. - Mild infusion‑site discomfort.

Serious or Rare Side Effects: - Severe hypersensitivity or anaphylactic reactions. - Acute hepatic failure. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Severe renal impairment. - Life‑threatening infusion‑related reactions. - Hematologic abnormalities such as neutropenia.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Renal function: assess baseline creatinine and adjust if necessary. Hepatic function: monitor liver enzymes regularly during treatment. Drug interactions: review concomitant medications for known interactions. Pregnancy: use only when the potential benefit outweighs the potential risk to the fetus. Infusion: administer under medical supervision with appropriate monitoring. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungina can interact with several agents, requiring careful management.

Major Interactions (Avoid): - Cyclosporine: may increase micafungin plasma concentrations, raising toxicity risk. - Rifampin: can markedly reduce micafungin levels, compromising efficacy. - Strong CYP3A4 inducers (e.g., carbamazepine): may lower micafungin exposure.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may alter micafungin metabolism, requiring dose adjustment. - Warfarin: potential for altered anticoagulant effect; monitor INR closely.